Stock AnalizBIO-TECHNE (TECH) earnings for the quarter ended September 2026: EPS misses estimates
BIO-TECHNE reported results for the quarter ended September 2026 on November 6, 2026. Adjusted earnings per share came in at $0.44 against the analysts’ average forecast of $0.45, a miss of 1.7%.
Revenue for the quarter was $300 million, up 4.6% from $287 million in the same quarter a year earlier.
The market’s verdict: the stock rose 0.0% on the first trading day after the report.
The last four quarters
BIO-TECHNE has beaten the analysts’ EPS forecast in 1 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.44 | $0.45 | −1.7% | +5% | +0.0% |
| Jun 2026 | $0.52 | $0.52 | +0.1% | +1% | +0.0% |
| Mar 2026 | $0.53 | $0.53 | −0.8% | −2% | −10.2% |
| Dec 2025 | $0.46 | $0.43 | +5.8% | −0% | +1.9% |
What comes next
Analysts expect EPS of $0.47 for the next quarter on average and $2.03 for the fiscal year ending June 30, 2027.
The average analyst price target is $70.50, 3% below the current price of $72.80.
Valuation and score
BIO-TECHNE scores 2.6 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 66.8, and its intrinsic value under moderate assumptions is about 60% below the current market value. Full BIO-TECHNE analysis with 10 years of financials
Frequently asked questions
What was BIO-TECHNE’s EPS for the quarter ended September 2026?
$0.44 adjusted per share, against an analyst consensus of $0.45.
How much revenue did BIO-TECHNE report?
$300 million, up 4.6% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.